Evidence map›Paper›PMID 40497995›Full record

ArticleCells2025

A Novel Primary Cell Line Model of Localized Prostate Cancer and Radioresistance-A Role for Nicotinamide N-Methyltransferase.

Jessica A Wright, Stephanie D White, Gavin Frame, Ana Bosiljkov, Shahbaz Khan, Roni Haas, Qian Yang, Minzhi Sheng, Xiaoyong Huang, Geoff S Higgins and 9 more

Abstract read
In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jessica A WrightSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0002-5413-4739
Stephanie D WhiteSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0002-0738-4380
Gavin FrameSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Ana BosiljkovSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Shahbaz KhanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Roni HaasDepartments of Human Genetics and Urology, University of California, Los Angeles, CA 90095, USA.ORCID 0000-0003-1505-2965
Qian YangSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Minzhi ShengSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0002-5668-1314
Xiaoyong HuangSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Geoff S HigginsDepartment of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Ian MillsNuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 7DQ, UK.ORCID 0000-0001-5347-5083
Michelle R DownesSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Danny VespriniSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0001-9714-2782
Hans T ChungSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Robert A ScreatonSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.
Hon S LeongSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0001-7801-1402
Paul C BoutrosDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada.ORCID 0000-0003-0553-7520
Thomas KislingerDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5G 2C4, Canada.ORCID 0000-0003-3525-5540
Stanley K LiuSunnybrook Research Institute, Toronto, ON M4N 3M5, Canada.ORCID 0000-0001-6851-0857

Funding

Canadian Cancer Society grant #708133Cancer Research UK C6078/A28736CIHR PJT-162384; PJT- 495955Prostate Cancer Canada D2017- 726 1811Prostate Cancer Canada RS2014-03
6 · The paper itself

Abstract

Prostate cancer cell lines are particularly clinically homogenous, mostly representing metastatic states rather than localized disease. While there has been significant work in the development of additional models, few have been created without oncogenic transformation. We derived a primary prostate cancer cell line from a patient with localized Gleason 7 prostate cancer-designated CaB34-which spontaneously immortalized. We leveraged CaB34 to generate a paired radioresistant subline, CaB34-CF, using a clinically relevant fractionated radiotherapy schedule. These two paired cell lines were investigated extensively to determine their molecular characteristics and therapy responses. Both CaB34 and CaB34-CF express prostate-specific markers, including KRT18, NKX3.1, and AMACR. Multi-omic analyses using RNAseq and shotgun proteomics identified NNMT as the most significantly dysregulated component in CaB34-CF. A bioinformatic analysis determined that NNMT was more abundant within prostate tumors compared to benign prostate, suggesting a role in tumor progression. Knockdown studies of NNMT demonstrated significant radiosensitization of CaB34-CF cells, which was largely a result of increased radiation-induced cellular senescence. Growth as 3D organoids was significantly higher in the CaB34-CF line, and demonstrated a less structured pattern of expression of cytokeratin markers. Radiosensitization with NNMT siRNA was recapitulated in a 3D organoid clonogenic assay in CaB34-CF cells. Our research provides a paired primary model of treatment-naïve and radioresistant disease to address mechanisms of therapy resistance, while expanding the repertoire of localized prostate cancer cell lines for the research community. In addition, our findings present NNMT as a potential therapeutic target for sensitization of radioresistant disease.

Indexed as

Models, BiologicalNicotinamide N-MethyltransferaseProstatic NeoplasmsRadiation ToleranceCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleNicotinamide N-Methyltransferasecell culturepreclinical modelsprostate cancerradiotherapy

Identifiers

PMID40497995
PMCPMC12153919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.